Vertex Pharmaceuticals has authorized an additional share repurchase program of up to $4 billion.
The program does not have an expiration date and can be discontinued at any time, the Boston-based company said.
The biotechnology company in 2023 authorized a program to repurchase up to $3 billion in stock. As of this week, about $775 million remained in that program. The newly authorized program will add to that total.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.